|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.730 USD | +0.70% |
|
+7.50% | -28.02% |
| 06-16 | DiaMedica Therapeutics Inc. Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program | CI |
| 06-16 | DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements | MT |
| Market Cap | 433M 309M 266M 245M 230M 29.14B 437M 2.9B 1.13B 14.3B 1.16B 1.13B 49.47B | P/E 2026 * |
-6.9x | P/E 2027 * | -6.51x |
|---|---|---|---|---|---|
| Enterprise Value | 433M 309M 266M 245M 230M 29.14B 437M 2.9B 1.13B 14.3B 1.16B 1.13B 49.47B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
56.7% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: DiaMedica Therapeutics Inc.
| 1 day | +0.70% | ||
| 1 week | +7.50% | ||
| Current month | -4.34% | ||
| 1 month | -5.45% | ||
| 3 months | -19.97% | ||
| 6 months | -30.21% | ||
| Current year | -28.02% |
| 1 week | 5.36 |  | 5.95 |
| 1 month | 5.24 | | 6.44 |
| Current year | 5.24 | | 9.04 |
| 1 year | 3.48 | | 10.42 |
| 3 years | 1.94 | | 10.42 |
| 5 years | 1.12 | | 10.42 |
| 10 years | 1.12 | | 13.77 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 54 | 01/01/2010 |
Scott Kellen
DFI | Director of Finance/CFO | 60 | 01/04/2018 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 12/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Giuffre
BRD | Director/Board Member | 70 | 10/08/2010 |
Rick Pauls
CHM | Chairman | 54 | 01/04/2008 |
James Parsons
CHM | Chairman | 60 | 01/01/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-01 | Free | Director | 40,412 | - | ||
| 06-01 | Option | Director | 40,412 | 0.0750% | ||
| 06-01 | Free | Chief Financial Officer | 162,000 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.70% | +7.50% | +60.50% | +63.71% | 309M | |
| +0.23% | +0.88% | +65.48% | +117.27% | 56.24B | |
| +0.04% | +1.20% | +47.67% | +36.75% | 43.76B | |
| +3.04% | +7.05% | -12.15% | -18.06% | 23.32B | |
| +3.07% | +7.15% | -1.82% | +392.25% | 21.34B | |
| +3.22% | +2.94% | +24.02% | -34.00% | 15.75B | |
| +0.53% | +1.92% | +16.31% | -37.64% | 15.6B | |
| +0.65% | -0.27% | +26.80% | +174.70% | 13.18B | |
| +3.07% | +5.43% | +21.37% | - | 12.01B | |
| +1.92% | +2.43% | +112.68% | +232.59% | 11.87B | |
| Average | +1.65% | +3.59% | +36.09% | +103.06% | 21.34B | |
| Weighted average by Cap. | +1.32% | +2.97% | +37.71% | +99.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -63.21M -45.06M -38.87M -35.74M -33.64M -4.25B -63.74M -424M -165M -2.09B -169M -165M -7.22B | -78.02M -55.62M -47.98M -44.11M -41.52M -5.25B -78.68M -523M -204M -2.58B -209M -204M -8.91B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/06/26 | 5.730 $ | +0.70% | 184,869 |
| 16/06/26 | 5.690 $ | +1.07% | 187,982 |
| 15/06/26 | 5.630 $ | -0.35% | 185,767 |
| 12/06/26 | 5.650 $ | +3.48% | 105,015 |
| 11/06/26 | 5.460 $ | +2.44% | 148,688 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DMAC Stock
Select your edition
All financial news and data tailored to specific country editions
